Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04119336 · ClinicalTrials.gov registry record · Phase 2
Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma
A Phase 2 study, sponsored by Andrew Yee, MD.
- Terminated
- Registry status
- Phase 2
- Development phase
- 2
- Enrollment target
NCT04119336 is a Phase 2 study that was terminated before completion, run by Andrew Yee, MD. The registered enrollment target is 2 participants.
The verdict
NCT04119336, a Phase 2 study, was terminated before completion, sponsored by Andrew Yee, MD.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 2 participants
- Enrollment target
Study Summary
This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
Interventions
- DRUG Cyclophosphamide
- DRUG Nivolumab
- DRUG Dexamethasone
- DRUG Ixazomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2020-02-14 |
| Est. Completion | 2022-03-30 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04119336
The ClinicalTrials.gov registry entry for NCT04119336 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Andrew Yee, MD, which has 2 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Cyclophosphamide is the first listed.
NCT04119336 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04119336 about?
NCT04119336 is a clinical study titled "Nivolumab, Ixazomib, Cyclophosphamide, and Dexamethasone in Relapsed/Refractory Myeloma". This research is being done to assess the effectiveness and safety of the combination of nivolumab with ixazomib, cyclophosphamide, and dexamethasone in relapsed and refractory multiple myeloma.
What is the current status of trial NCT04119336?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 2 participants. The study started on 2020-02-14. Estimated completion is 2022-03-30.
What interventions are being tested in trial NCT04119336?
The interventions under investigation include: Cyclophosphamide (DRUG), Nivolumab (DRUG), Dexamethasone (DRUG), Ixazomib (DRUG).
Who is sponsoring clinical trial NCT04119336?
This trial is sponsored by Andrew Yee, MD, which has 2 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.